Recombinant Human Apolipoprotein A-V (APOA5)

Uniprot Id

Q6Q788

Target Species

Human

Target Name

APOA5

Target Full Name

Apolipoprotein A-V

Target Function

Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and an inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages. Binds heparin.

Target Involvement

Hypertriglyceridemia, familial (FHTR); Hyperlipoproteinemia 5 (HLPP5)

Target Subcellular Location

Secreted. Early endosome. Late endosome. Golgi apparatus, trans-Golgi network.

Target Protein Families

Apolipoprotein A1/A4/E family

Target Tissue Specificity

Liver and plasma.

Target Research Area

Cancer

Target Synonyms

Apo-AV; ApoA-V; Apoa5; APOA5_HUMAN; ApoAV; Apolipoprotein A-V; Apolipoprotein A5; RAP3; Regeneration associated protein 3; Regeneration-associated protein 3

Target Background

The protein encoded by this gene is an apolipoprotein that plays an important role in regulating the plasma triglyceride levels, a major risk factor for coronary artery disease. It is a component of high density lipoprotein and is highly similar to a rat protein that is upregulated in response to liver injury. Mutations in this gene have been associated with hypertriglyceridemia and hyperlipoproteinemia type 5. This gene is located proximal to the apolipoprotein gene cluster on chromosome 11q23. Alternatively spliced transcript variants encoding the same protein have been identified.